5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4023-4034

  Nilsson, Björn M ^a  

^a BIOVITRUM AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; AZEPINOINDOLE; CABERGOLINE; DEXFENFLURAMINE; LYSERGIDE; MESCALINE; ORG 12962; ORG 36262; ORG 37684; PERGOLIDE; PIPERAZINE DERIVATIVE; PNU 22394A; QUIPAZINE; SEROTONIN 1A AGONIST; SEROTONIN 1B AGONIST; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2B ANTAGONIST; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DRUG TOLERANCE; HALLUCINATION; HUMAN; HYPOPHAGIA; NONHUMAN; OBESITY; PULMONARY HYPERTENSION; SATIETY; SHORT SURVEY; VALVULAR HEART DISEASE;

ANIMALS; ANTI-OBESITY AGENTS; HUMANS; LIGANDS; OBESITY; RECEPTOR, SEROTONIN, 5-HT2C;

EID: 33745838246     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058240i     Document Type: Short Survey

References (140)

1. Bays, H.; Dujovne, C. Pharmacotherapy of obesity: currently marketed and upcoming agents. Am. J. Cardiovasc. Drugs 2002, 2, 245-253.
2. Kaya, A.; Aydin, N.; Topsever, P.; Filiz, M.; Ozturk, A.; Dagar, A.; Kilinc, E.; Ekmekcioglu, C. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed. Pharmacother. 2004, 58, 582-587.
3. Clark, D. W. J.; Harrison-Woolrych, M. Sibutramine may be associated with memory impairment. BMJ 2004, 329, 1316.
4. Satici, A.; Yilmaz, N.; Guzey, M.; Karadede, S.; Kilic, A. The effect of sibutramine, a new anti-obesity drug, on intraocular pressure. Int. J. Obes. 2000, 24 (Suppl. 1), S105.
5. Oh, S. W.; Lee, S.; Park, C.; Kim, D. J. Elevated intraocular pressure is associated with insulin resistance and metabolic syndrome. Diabetes Metab. Res. Rev. 2005, 21, 434-440.
6. Van Gaal, L. F.; Rissanen, A. M.; Scheen, A. J.; Ziegler, O.; Rössner, S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365, 1389-1397.
7. Sanofi-Aventis: rimonabant accepted for filing by the FDA. Press Release, June 23, 2005.
8. 1C receptors and their therapeutic relevance. Curr. Opin. Invest. Drugs 1993, 2, 317-362.
9. 2C agonists as potential antidepressants. IDrugs 1999, 2, 109-120.
10. 2C receptor as a potential therapeutic target for the design of antiobesity and antiepileptic drugs. Drugs Future 2001, 26, 383-393.
11. 2C receptor modulators: progress in development of new CNS medicines. Annu. Rep. Med. Chem. 2002, 37, 21-30.
12. 2C receptor agonists as potential drugs for the treatment of obesity. Curr. Top. Med. Chem. 2003, 3, 885-897.
13. 2C receptor agonists. Expert Opin. Ther. Pat. 2003, 13, 1691-1705.
14. 2C receptors as a potential therapeutic target for the design antiepileptic drugs. Curr. Top. Med. Chem. 2005, 5, 59-67.
15. Halford, J. C. G.; Harrold, J. A.; Lawton, C. L.; Blundell, J. E. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets 2005, 6, 201-213.
16. 2C receptor agonists: potential for the treatment of obesity. Mol. Interventions 2005, 5, 282-291.
17. Barnes, N. M.; Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38, 1083-1152.
18. Raymond, J. R.; Mukhin, Y. V.; Gelasco, A.; Turner, J.; Collinsworth, G.; Gettys, T. W.; Grewal, J. S.; Garnovskaya, M. N. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther. 2001, 92, 179-212.
19. 2 receptors. Curr. Drug Targets: CNS Neurol. Disord. 2004, 3, 11-26.
20. Pazos, A.; Hoyer, D.; Palacios, J. M. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur. J. Pharmacol. 1984, 106, 539-546.
21. Humphrey, P. P.; Hartig, P.; Hoyer, D. A proposed new nomenclature for 5-HT receptors. Trends Pharmacol. Sci. 1993, 14, 233-236.
22. 1C receptor subtypes. Biochem. Biophys. Res. Commun. 1991, 181, 1469-1478.
23. 1C receptors in choroid plexus epithelium. J. Neurosci. 1992, 12, 4775-4782.
24. 2C serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Res. 2002, 951, 135-140.
25. Sw mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J. Neurosci. 2004, 24, 7707-7717.
26. Hikiji, K.; Inoue, K.; Iwasaki, S.; Ichihara, K.; Kiriike, N. Local perfusion of mCPP into ventromedial hypothalamic nucleus, but not into lateral hypothalamic area and frontal cortex, inhibits food intake in rats. Psychopharmacology (Berlin) 2004, 174, 190-196.
27. 2C receptor mRNAs in mice prone, or resistant, to chronic high-fat diet-induced obesity. Brain Res. Mol. Brain Res. 2004, 127, 39-47.
28. 2C receptors in CHO-K1 cells. Br. J. Pharmacol. 1999, 128, 13-20.
29. Leibowitz, S. F.; Weiss, G. F.; Shor-Posner, G. Hypothalamic serotonin: pharmacological, biochemical, and behavioral analyses of its feeding-suppressive action. Clin. Neuropharmacol. 1988, 11 (Suppl. 1), S51-S71.
30. Heisler, L. K.; Cowley, M. A.; Tecott, L. H.; Fan, W.; Low, M. J.; Smart, J. L.; Rubinstein, M.; Tatro, J. B.; Marcus, J. N.; Holstege, H.; Lee, C. E.; Cone, R. D.; Elmquist, J. K. Activation of central melanocortin pathways by fenfluramine. Science 2002, 297, 609-611.
31. Kaplan, J. M.; Song, S.; Grill, H. J. Serotonin receptors in the caudal brainstem are necessary and sufficient for the anorectic effect of peripherally administered mCPP. Psychopharmacology (Berlin) 1998, 137, 43-49.
32. Saper, C. B.; Chou, T. C.; Elmquist, J. K. The need to feed: homeostatic and hedonic control of eating. Neuron 2002, 36, 199-211.
33. 2C receptors. Eur. J. Pharmacol. 2003, 480, 151-162.
34. 2C serotonin receptors. Nature 1995, 374, 542-546.
35. 2C receptor mutant mice. Diabetes 2003, 52, 315-320.
36. 2C receptor mutant mice. Biochem. Biophys. Res. Commun. 2002, 295, 249-254.
37. 2C receptor gene. Nat. Med. 1998, 4, 1152-1156.
38. 2 receptor agonists using the post-prandial satiety sequence in rats. Psychopharmacology (Berlin) 1994, 113, 369-377.
39. Hewitt, K. N.; Lee, M. D.; Dourish, C. T.; Clifton, P. G. Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol. Biochem. Behav. 2002, 71, 691-700.
40. Vickers, S. P.; Benwell, K. R.; Porter, R. H.; Bickerdike, M. J.; Kennett, G. A.; Dourish, C. T. Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats. Br. J. Pharmacol. 2000, 130, 1305-1314.
41. 2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology (Berlin) 2003, 167, 274-280.
42. 2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology (Berlin) 1997, 133, 309-312.
43. Gallant, D. M.; Bishop, M. P.; Bishop, G.; O'Meallie, L. U-22,394A: a controlled evaluation in chronic schizophrenic patients. Curr. Ther. Res. Clin. Exp. 1967, 9, 579-581.
44. 2C receptor agonist, reduces feeding in rodents and produces weight loss in humans. Soc. Neurosci. Abstr. 2001, 27, 309.2.
45. 2C receptor antagonist. Neuropharmacology 1997, 36, 609-620.
46. Abenhaim, L.; Moride, Y.; Brenot, F.; Rich, S.; Benichou, J.; Kurz, X.; Higenbottam, T.; Oakley, C.; Wouters, E.; Aubier, M.; Simonneau, G.; Begaud, B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 1996, 335, 609-616.
47. Connolly, H. M.; Crary, J. L.; McGoon, M. D.; Hensrud, D. D.; Edwards, B. S.; Edwards, W. D.; Schaff, H. V. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 1997, 337, 581-588.
48. 2C receptors. Neuropharmacology 2001, 41, 200-209.
49. 2C receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 370, 114-123.
50. Bray, G. A.; Ryan, D. H. Drugs used in the treatment of obesity. Diabetes Rev. 1997, 5, 83-103.
51. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000, 102, 2836-2841.
52. 2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 2000, 57, 75-81.
53. 2B receptor activation plays crucial role. Mov. Disord. 2004, 19, 1523-1524.
54. Launay, J. M.; Herve, P.; Peoc'h, K.; Tournois, C.; Callebert, J.; Nebigil, C. G.; Etienne, N.; Drouet, L.; Humbert, M.; Simonneau, G.; Maroteaux, L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 2002, 8, 1129-1135.
55. Setola, V.; Roth, B. L. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on "fen- phen". Expert Opin. Drug Metab. Toxicol. 2005, 1, 377-387.
56. 2, receptor subtypes. J. Pharmacol. Exp. Ther. 2002, 303, 815-822.
57. Horvath, J.; Fross, R. D.; Kleiner-Fisman, G.; Lerch, R.; Stalder, H.; Liaudat, S.; Raskoff, W. J.; Flachsbart, K. D.; Rakowski, H.; Pache, J. C.; Burkhard, P. R.; Lang, A. E. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. 2004, 19, 656-662.
58. Rochester, J. A.; Kirchner, J. T. Ecstasy (3,4- methylenedioxymethamphetamine): history, neurochemistry, and toxicology. J. Am. Board Fam. Pract. 1999, 12, 137-142.
59. Setola, V.; Hufeisen, S. J.; Grande-Allen, K. J.; Vesely, I.; Glennon, R. A.; Blough, B.; Rothman, R. B.; Roth, B. L. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 2003, 63, 1223-1229.
60. 2 receptor and its signaling pathway in aortic valve interstitial cells. Am. J. Pathol. 2002, 161, 2209-2218.
61. Aghajanian, G. K.; Marek, G. J. Serotonin and hallucinogens. Neuropsychopharmacology 1999, 21 (Suppl. 2), 16S-23S.
62. 2A receptor and its antagonists in the cardiovascular system. Pharmacol. Ther. 2004, 104, 59-81.
63. 3H]phosphatidylinositols. Naunyn-Schmiedeberg's Arch. Pharmacol. 2002, 365, 242-252.
64. Conn, P. J.; Sanders-Bush, E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J. Pharmacol. Exp. Ther. 1987, 242, 552-557.
65. 2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berlin) 1995, 119, 222-230.
66. 1B receptor ligands exist? Naunyn-Schmiedeberg's Arch. Pharmacol. 1989, 339, 675-683.
67. 2) structure-function relationships of the nitro and amino phenylpiperazines on intact human platelets. Biochem. Pharmacol. 1989, 38, 4237-4244.
68. Cohen, M. L.; Fuller, R. W. Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethyl-phenylpiperazine. Life Sci. 1983, 32, 711-718.
69. 2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery. J. Pharm. Pharmacol. 1995, 47, 310-316.
70. Vane, J. R. The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation. Br. J. Pharmacol. 1959, 14, 87-98.
71. 2B) in rat stomach fundus longitudinal muscle. Br. J. Pharmacol. 1994, 112, 323-331.
72. Simansky, K. J.; Schechter, L. E. Properties of some 1-arylpiperazines as antagonists of stereotyped behaviors mediated by central serotonergic receptors in rodents. J. Pharmacol. Exp. Ther. 1988, 247, 1073-1081.
73. 1C-receptors in drug-induced penile erections in rats. Psychopharmacology (Berlin) 1990, 101, 57-61.
74. 2 receptor subfamily. Life Sci. 1996, 59, 1081-1095.
75. 2 receptor subtypes. Eur. J. Pharmacol. 2001, 414, 23-30.
76. Burns, C. M.; Chu, H.; Rueter, S. M.; Hutchinson, L. K.; Canton, H.; Sanders-Bush, E.; Emeson, R. B. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 1997, 387, 303-308.
77. 2C receptor. Neuropsychopharmacology 1999, 21 (Suppl. 2), 82S-90S.
78. 2B receptor. NeuroReport 1996, 7, 1457-1460.
79. 2C receptor agonists. Pharmacol. Biochem. Behav. 2001, 69, 643-652.
80. Moser, L. R.; Kaiser, J. A.; Hardy, R. A., Jr. Process for Producing Anorexia. U.S. Patent 3,253,989, 1966 (American Cyanamid Co.).
81. Lumma, W. C., Jr.; Saari, W. S. 6-Chloro-2-(1-piperazinyl)pyrazine. U.S. Patent 4,082,844, 1978 (Merck and Co., Inc.).
82. 1B receptors. Psychopharmacology (Berlin) 1988, 96, 93-100.
83. 1C receptors mediate 1-(3-chlorophenyl)piperazine-induced hypophagia. Br. J. Pharmacol. 1991, 103, 2016-2020.
84. Samanin, R.; Bendotti, C.; Miranda, F.; Garattini, S. Decrease of food intake by quipazine in the rat: relation to serotoninergic receptor stimulation. J. Pharm. Pharmacol. 1977, 29, 53-54.
85. 2 receptor subtype data on m-CPP, MK-212, TFMPP and quipazine, see ref 28.
86. Horrom, B. W.; Wright, H. B. Anorexigenic N-3,4-Dihalophenylpiperazines. U.S. Patent 3,637,705, 1972 (Abbott Laboratories).
87. Najer, H.; Giudicelli, J. F. Anorectic N-(m-Chlorophenyl)-N'-(β- cyanoethyl)piperazine salts. British Patent GB 1378976, 1975 (Synthelabo S. A.).
88. 3 serotonin receptors: results of a structure-affinity study. Eur. J. Pharmacol. 1989, 168, 387-392.
89. Carlier, P.; Monteil, A. J. C.; Poisson, C. Pharmaceutical composition containing 1-[mono- or bis(trifluoromethyl)-2-pyridinyl]piperazines as central nervous system agents. European Patent EP 370560, 1990 (AKZO N.V., The Netherlands).
90. 2C receptor as potential antidepressants and anxiolytics. In Trends in Drug Research 11, Proceedings of the 11th Noordwijkerhout-Camerino Symposium; van der Goot, H., Ed.; Elsevier: Amsterdam, 1998; Vol. 29, pp 49-61.
91. Marsden, C. A.; Stanford, S. C. CNS drugs III; psychotherapeutics. Expert Opin. Invest. Drugs 2000, 9, 1923-1929.
92. 2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26, 441-449.
93. Hache, J.; Diamantis, W.; Sofia, D.; Streichenberger, G. The pharmacology of 1841 CERM, a new analgesic. Arzneimittelforschung 1978, 28, 642-645.
94. 2C receptor agonists: pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp. Ther. 1998, 286, 913-924.
95. 2C receptor agonists by the incorporation of a gem-dimethyl group: SAR using the Ames test and a DNA unwinding assay. Mutagenesis 1998, 13, 397-403.
96. 2C receptor agonist and d-fenfluramine on feeding patterns in the rat. Psychopharmacology (Berlin) 2000, 152, 256-267.
97. 2C receptor agonists for the treatment of obesity. Bioorg. Med. Chem. Lett. 2005, 15, 1467-1470.
98. Hoegerle, K.; Habicht, E. Anorexigenic Tetrahydrobenzazepines. U.S. Patent 3,716,639, 1973 (Ciba-Geigy Corp.).
99. 2C Receptor Agonists. PCT Int. Appl. WO 2002074746, 2002 (Yamanouchi Pharmaceutical Co., Ltd., Japan).
100. 2C receptor agonist. PCT Int. Appl. WO 2005019180, 2005 (Eli Lilly and Company).
101. 2C receptor agonists. PCT Int. Appl. WO 2005082859. 2005 (Eli Lilly and Company).
102. For other structurally related 3-benzazepines, see the following, (a) Mentrup, A.; Schromm, K.; Renth, E.-O.; Reichl, R. Anorectic 7-Acyl-1,2,4,5-tetrahydro-3H-3-benzazepines. U.S. Patent 3,766,170, 1973 (Boehringer Ingelheim).
103. (b) Ward, J. G.; Young, R. C.; Kaumann, A. J. Preparation of 2,3,4,5-Tetrahydro-1H-benzazepines as drugs. PCT Int. Appl. WO 9300094, 1993 (SmithKline Beecham).
104. DeMarinis, R. M.; Hieble, P. J.; Matthews, W. D. 6-Chloro-2,3,4,5- tetrahydro-3-methyl-1H-3-benzazepine: a potent and selective antagonist of 0.2-adrenoceptors. J. Med. Chem. 1983, 26, 1213-1214.
105. 2C receptors. Psychopharmacology (Berlin) 2001, 156, 58-62.
106. For a review, see the following. Jandacek, R. J. APD-356 (Arena). Curr. Opin. Invest. Drugs 2005, 6, 1051-1056.
107. 2C receptor modulators by the U.S. Patent Office. Press Release, October 11, 2005.
108. 2C receptor modulators. U.S. Patent 6,953,787, 2005 (Arena Pharmaceuticals, Inc.).
109. Arena Pharmaceuticals Inc. announces positive phase II clinical trial results of a novel antiobesity compound. Press Release, May 11, 2005.
110. Arena Pharmaceuticals Inc.'s APD356 phase IIa clinical trial data were presented at the 2005 NAASO Annual Meeting. Press Release, October 18, 2005.
111. Arena Pharmaceuticals Inc. announces positive phase IIb clinical trial results of a novel antiobesity compound. Press Release, December 13, 2005.
112. 2C receptor agonist as a potential new treatment for obesity. Soc. Neurosci. Abstr. 2003, 29, 509.4.
113. 2C Receptor Associated Diseases. PCT Int. Appl. WO 2005016902, 2005 (Arena Pharmaceuticals Inc.).
114. 2C receptor agonists for the treatment of obesity. Biological and chemical adventures. Chimia 2004, 58, 613-620.
115. 2C receptor agonists. Bioorg. Med. Chem. Lett. 2004, 14, 2367-2370.
116. 2C receptor agonists. Bioorg. Med. Chem. Lett. 2006, 16, 1207-1211.
117. Norman, P. Medicinal Chemistry in Eastern England-15th Symposium. IDrugs 2004, 7, 534-537.
118. Sarabu, R. Metabolic Diseases Drug Discovery World Summit. July 28-29, 2003, San Diego, CA. Expert Opin. Invest. Drugs 2003, 12, 1721-1726.
119. 2C receptor agonist WAY-161503. Brain Res. 2006, 1073-1074, 240-251.
120. 117
121. 2C receptor. Bioorg. Med. Chem. Lett. 2004, 14, 2603-2607.
122. Dunlop, J.; Sabb, A. L.; Mazandarani, H.; Zhang, J.; Kalgaonker, S.; Shukhina, E.; Sukoff, S.; Vogel, R. L.; Stack, G.; Schechter, L.; Harrison, B. L.; Rosenzweig-Lipson, S. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro- 7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]-indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J. Pharmacol. Exp. Ther. 2005, 313, 862-869.
123. 2C receptor agonist. Soc. Neurosci. Abstr. 2003, 29, 509.9.
124. Biovitrum AB completes successful phase IIa trial for antiobesity treatment. Press Release, February 27, 2002.
125. 2C receptor agonists with therapeutic uses. PCT Int. Appl. WO 2004000830, 2004 (Biovitrum AB, Sweden).
126. 2C receptor agonist. Eur. J. Pharmacol. 2004, 483, 37-43.
127. 2C receptor agonist, in Zucker rats. Brain Res. 2004, 1011, 221-227.
128. 2C-receptor agonist, in rats. J. Pharm. Pharmacol. 2004, 56, 1551-1556.
129. 2C receptor agonists for the treatment of obesity. Abstracts of Papers, 221 st National Meeting of the American Chemical Society, San Diego, CA, April 1-5, 2001; MED1-105.
130. 2C receptor agonists for obesity. Abstracts of Papers, 229th National Meeting of the American Chemical Society, San Diego, CA, March 13-17, 2005; MEDI-283.
131. A-37215. Drug Data Report; Prous Science: Barcelona, 2005; Vol. 27, p 302.
132. 2C receptor modulators. U.S. Patent Application US 2006/0003990 A1, 2006 (Athersys, Inc.).
133. Bennani, Y. L.; Huck, B.; Robarge, M. J. Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators. U.S. Patent Application US 2006/0025601 A1. 2006 (Athersys, Inc.).
134. Maggio, A. Obesity Drug Development Summit, Arlington, VA, July 21-22, 2005. IDdb Meeting Report, Reference Number RF615275. The Investigational Drugs Database (IDdb3). http://www.iddb3.com.
135. Dohrmann, C. Obesity and Weight Loss-Second Annual World Congress, Washington, DC, September 12-14, 2005. IDdb Meeting Report, Reference Number RF623634. The Investigational Drugs Database (IDdb3). http://www.iddb3.com.
136. However, according to a recent clinical study, the addition of orlistat to sibutramine did not significantly induce further weight loss (or improve the maintenance of weight loss) compared with the continued use of sibutramine alone. Wadden, T. A.; Berkowitz, R. I.; Womble, L. G.; Sarwer, D. B.; Arnold, M. E.; Steinberg, C. M. Effects of sibutramine plus orlistat in obese women following I year of treatment by sibutramine alone: a placebo-controlled trial. Obes. Res. 2000, 8, 431-437.
137. USAN Council approves nonproprietary name lorcaserin hydrochloride for Arena's drug candidate APD356. Press Release, May 5, 2006.
138. American Medical Association: statement on a nonproprietary name adopted by the USAN Council. Available at: http://www. ama-assn.org/amal/pub/upload/mm/ 365/lorcaserin_hydrochlo.pdf. Accessed May 27, 2006.
139. 2C receptor agonists. Bioorg. Med. Chem. Lett. 2006, 16, 2891-2894.
140. 2C agonists in treating obesity. Expert Opin. Invest. Drugs 2006, 15, 257-266.